Redeye remains confident on the case and leave our forecasts and valuation virtually unchanged following the Q2 report. Sales and earnings were basically as expected while order bookings improved across the board. Ependion’s near-term outlook remains cautious, but we sense a bit more optimism as business activity is high and the Group is exposed to several markets with solid underlying structural growth.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/